Showing results (61-70 of 604) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|November 29, 2023
Developing a Natural History Model for Duchenne Muscular DystrophyJonathan Broomfield, M Hill, F Chandler, et al.
Pharmacoeconomics - Open|January 16, 2024
From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in ItalyElvio Emanuele Rossini, Carlotta Galeone, Chiara Lucchetti, et al.
Pharmacoeconomics - Open|March 4, 2024
Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK AnalysisChristian Bührer, Thomas Paling, Richard Gale, et al.
Pharmacoeconomics - Open|December 7, 2023
United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life InstrumentMadeleine T King, D A Revicki, R Norman, et al.
Pharmacoeconomics - Open|July 23, 2024
Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore StoryShe Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, et al.
Pharmacoeconomics - Open|July 13, 2024
Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in SingaporeClarence Ong, Jamaica Briones, Zhi Zhen Lim, et al.
Pharmacoeconomics - Open|July 1, 2024
A Cost Evaluation of COVID-19 Remote Home Monitoring Services in EnglandSonila M Tomini, Efthalia Massou, Nadia E Crellin, et al.
Pharmacoeconomics - Open|June 3, 2024
Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in ArgentinaCarlos Rojas-Roque, Constanza Silvestrini, Fernando Argento, et al.
Pharmacoeconomics - Open|July 11, 2024
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario SimulationRichard Nicholas, Erik Scalfaro, Rachel Dorsey, et al.
Pharmacoeconomics - Open|July 4, 2024
A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in FrancePaul Casabianca, Marc Massetti, François-Emery Cotte, et al.
Pageof 61